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• The MITF, p.E318K mutation has been described as a rare risk 
factor for melanoma and renal cell carcinoma 2.
• Associated risks for the MITF, p.E318K mutation have been 
mostly ascertained by studying melanoma cohorts 1-3. 
• Little is known about the incidence of MITF, p.E318K or the 
natural history of MITF, p.E318K carriers in non-melanoma 
cohorts. 
• We describe three cases where the MITF, p.E318K mutation was 
incidentally identified during hereditary cancer risk assessment. 
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• As multigene panel testing continues to gain popularity in clinical
practice, incidental pathogenic variants are also more commonly
identified.
• The challenge of incidental findings is heightened in genes with
limited data on lifetime risks and incomplete penetrance.
• We highlight the importance of the development of clinical
guidelines for newly described hereditary cancer genes to
standardize recommendations, better understand risks for carriers
in other populations, and justify medical necessity for
management changes based on incidental genetic test results.
• Limitations:
• Small sample size. Limited data on longitudinal follow-up to assess
the clinical impact of incidental findings.
• We would like to thank our patients for their engagement in genetic risk
assessment. We would also like to thank our entire team at the Division 
of Clinical Genetics for their tireless support!
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Case 1 Case 2 Case 3
Age 49 43 52
Gender (M/F) Female Female Female
Ethnicity/ Race Hispanic White
Hispanic
White Hispanic White










for Mismatch Repair 
(MMR) genes



















Newly diagnosed colon cancer. Family 
history of colon, endometrial, and breast 
cancer. 
Met HBOC genetic testing 
NCCN guidelines at 
assessment? 
Yes Yes No
Met Lynch Syndrome genetic 
testing NCCN guidelines at 
assessment? 
No No Yes


































(vs. ~2.5% USA 
population risk)
Annual full body dermatologic 
exam
~20 y
(Median age of 









(Median age of 
onset 35-72 y 4)
Consideration of annual renal 
imaging with renal ultrasound. 
Consider alternating with MRI.
Consideration of annual urinalysis
* Based on available literature, geographic location, and screening guidelines for other genetic syndromes associated with 
melanoma and RCC
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